LETI-101: Life Edit’s Novel Gene Editing Approach to Huntington’s Disease Treatment

Drug Target Review recently published a byline article featuring LETI-101, Life Edit's development candidate for Huntington's disease (HD). HD is a rare, inherited neurodegenerative disorder affecting approximately 41,000 people in the United States, with another 200,000 at risk. LETI-101 uses Life Edit’s CRISPR technology for allele-selective editing, offering a novel approach to potentially treating this devastating condition. What sets LETI-101 apart is its precision targeting strategy. Rather than directly targeting the disease-causing CAG repeat expansion, LETI-101 targets single nucleotide polymorphisms (SNPs) that allow us to distinguish between mutant and healthy copies of the gene.

"A transformative aspect of our LETI-101 approach is that it's designed as a one-time treatment that could provide long-lasting benefit without the need for repeated administration," explains Dr. Amy Pooler, SVP of Research & Development at Life Edit. "Unlike other therapeutic modalities being developed for HD that would require ongoing treatment to maintain efficacy, our gene editing therapy is intended to make a permanent, precise modification to the DNA itself."